Evaxion A/S, a clinical-stage TechBio company, has announced positive preclinical data for its novel cytomegalovirus (CMV) vaccine program, EVX-V1. Using its proprietary AI-Immunology™ platform, Evaxion has identified entirely new CMV antigens that have demonstrated the ability to induce specific immune responses, inhibit viral infection, and reduce cell-to-cell spread in both cellular and animal models. The EVX-V1 vaccine candidate combines these AI-discovered antigens with AI-optimized versions of established vaccine targets, including a proprietary pre-fusion glycoprotein B (gB) antigen that has shown superior CMV neutralization compared to traditional gB antigens. Preclinical development is ongoing, with further antigen investigation and optimization underway. The company did not indicate whether these results have already been presented at a scientific meeting or will be presented in the future.